Chemoprevention with a Long Acting Somatostatin Analogue in a Multiple Endocrine Neoplasia Type 1 (MEN1) Knockout Mouse Model Does Delay the Progression of Pancreatic Neuroendocrine Neoplasms (pNENs) Abstract #1488

Introduction: Long acting somatostatin analogues (LAR) are an essential part of the treatment of neuroendocrine tumours.
Aim(s): The aim of this study was to evaluated the chemopreventive effects of a long acting somatostatin analogue on the development of pancreatic neuroendocrine neoplasms (pNENs) in a MEN1 Knockout mouse model.
Materials and methods: MEN1 knockout mice were treated with monthly subcutaneous injections of the somatostatin analogue Lanreotid (Somatuline Autogel ©;Ipsen Pharma) or a placebo, starting at day 35. Mice were killed after a determined period (after 6, 9, 12, 15 and 18 months, each group contained 5 mice) and size of pNENs were measured due histological analysis and compared to the control group.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: MD Caroline Lopez

To read results and conclusion, please login ...

Further abstracts you may be interested in

#14 Radioguided surgery in NET: First impression with Ga-68 labeled somatostatin analogues
Introduction: Neuroendocrine tumors (NET) constitute a heterogenous group of neoplasms. The development of Gallium-68-labeled somatostatin analogues, such as DOTA-NOC or DOTA-TOC, PET/CT have dramatically improved the diagnosis of neuroendocrine tumors. Surgery remains the treatment of choice for localized disease as well as metastatic disease. The aims of surgery are: improvement of symptoms, reduction of tumor mass / burden and to give better quality of life to patients. Recurrent laparotomies often lead to multiple adhesions and altered anatomy. So it is increasingly difficult for imaging physicians and surgeons to separate non-malignant from malignant tissue.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#44 Somatostatin analogue therapy and RAND-36 health-related quality of life scores in patients with neuroendocrine tumors
Introduction: Somatostatin analogues (SSAs) are used in patients with neuroendocrine tumors (NETs) for the management of carcinoid syndrome and/or delay of disease progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Yao J C, Beaumont J L, Choi S, Cella D, ...
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Joël Guigay
#532 Effect of the Combined Administration of mTOR Inhibitor and Dopamine or Somatostatin Analogues in a Human Bronchial Neuroendocrine Cell Line
Introduction: The mTOR inhibitor rapamycin (RAP) has been considered an anticancer agent. The role of dopamine and somatostatin in controlling cell secretion and proliferation in neuroendocrine tumors (NETs) is still unclear.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Prof Rosario Pivonello